OKYO director receives 6,500-share option grant
OKYO Pharma Ltd director John P. Brancaccio received a grant of options over 6,500 common shares at an exercise price of $1.85 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
OKYO Pharma Ltd director John P. Brancaccio received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options were awarded on June 8, 2026 and are scheduled to become exercisable on June 8, 2027, expiring on June 8, 2036. Following this compensation-related grant, Brancaccio holds options over 138,394 shares in total.
Insider Trade Summary
Grant/Award: 6,500 shares
Grant/Award
1 txn
Insider
BRANCACCIO JOHN P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option | 6,500 | $1.85 | $12K |
Holdings After Transaction:
Option — 138,394 contracts (Direct)
Key Figures
Option grant size: 6,500 options
Exercise price: $1.85 per share
Total options after grant: 138,394 options
+2 more
5 metrics
Option grant size
6,500 options
Grant of options over common shares on June 8, 2026
Exercise price
$1.85 per share
Strike price for newly granted options
Total options after grant
138,394 options
Holdings following the reported transaction
Option vesting date
June 8, 2027
Scheduled exercise start date
Option expiration date
June 8, 2036
Final date to exercise granted options
Key Terms
Option, Common Shares, Grant, award, or other acquisition, exercise price, +1 more
5 terms
Option financial
"security_title: "Option""
An option is a financial contract that gives its holder the right, but not the obligation, to buy or sell a stock at a specified price within a set time. Investors use options like a reservation or coupon to lock in a price, protect against losses, or amplify potential gains with a smaller upfront cost than owning the stock outright, making them useful for hedging, income strategies, or speculative bets.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "1.8500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did OKYO director John P. Brancaccio report on this Form 4 for OKYO?
Director John P. Brancaccio reported receiving a grant of options over 6,500 OKYO Pharma common shares. These options were awarded as a compensation-related grant, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.
What is the exercise price of the options granted to OKYO director John P. Brancaccio?
The options granted to John P. Brancaccio have an exercise price of $1.85 per share. This means he can buy OKYO Pharma common shares at that price if he exercises the options once they become exercisable.
When do John P. Brancaccio’s newly granted OKYO Pharma options vest and expire?
The granted options are scheduled to become exercisable on June 8, 2027. They have an expiration date of June 8, 2036, giving a long window during which Brancaccio can choose to exercise them if he wishes.
How many OKYO Pharma options does John P. Brancaccio hold after the reported grant?
After the reported grant, John P. Brancaccio holds options over 138,394 OKYO Pharma shares. This total reflects his position in derivative securities following the 6,500-share option award disclosed in the Form 4 filing.
Was the OKYO Pharma Form 4 transaction an open-market buy or a compensation grant?
The Form 4 transaction for OKYO Pharma reflects a compensation-related grant, coded as a “Grant, award, or other acquisition.” It is not an open-market purchase, but an option award giving the director future rights to acquire shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
